David Letterman Cardiometabolic Compounded vs Branded: What's Likely

What We Know About Letterman's Cardiac History

David Letterman is one of the few major public figures to discuss heart disease candidly and with humor. In January 2000, while still hosting the Late Show on CBS, he underwent a quintuple coronary artery bypass graft (CABG) procedure at New York, Presbyterian Hospital after discovering severely blocked arteries during a routine stress test. He returned to air six weeks later and has since credited his surgical team and ongoing medical management with his survival.

Letterman has confirmed in interviews that he takes a statin. He has joked about his cardiologist's role in his life with the same dry wit he applied to his guests. That kind of public disclosure, while not a formal medical record, gives clinicians and patients a useful starting point for understanding what post-CABG pharmacotherapy looks like in a real, high-profile case.

What a Quintuple CABG Means Clinically

A quintuple CABG means five separate coronary arteries or branches were bypassed using grafts, typically the left internal mammary artery and saphenous vein segments. Patients with five-vessel disease occupy the highest tier of atherosclerotic cardiovascular disease (ASCVD) risk. The ten-year recurrence rate of major adverse cardiac events (MACE) in this population without aggressive pharmacotherapy is substantial.

The ACC/AHA 2022 Guideline on the Management of Heart Failure and the 2019 ACC/AHA Primary Prevention Guideline both classify prior CABG as a very-high-risk ASCVD condition [1]. That classification drives specific drug choices.

Statin Therapy After CABG: The Non-Negotiable

Post-CABG guidelines from the AHA and ACC assign a Class I recommendation (strong, based on evidence of benefit) to high-intensity statin therapy for all patients who can tolerate it [2]. High-intensity statins are defined as those that reduce LDL-C by at least 50%.

The two agents that meet this threshold are atorvastatin 40 to 80 mg daily and rosuvastatin 20 to 40 mg daily [2]. Given that Letterman's surgery was in 2000, he may have started on an earlier statin like simvastatin, but current guidelines would strongly favor transitioning to one of these two agents.

Compounded vs Branded Statins: Does It Matter Here?

Statins are the area where the compounded-vs-branded debate is largely moot. Atorvastatin and rosuvastatin are both available as FDA-approved generics at very low cost. A 90-day supply of generic atorvastatin 80 mg runs under $15 at most major pharmacies. There is no clinical or economic reason to seek a compounded statin when generic equivalents are available, bioequivalent, and regulated under full FDA standards [3].

What FDA Bioequivalence Actually Requires

For a generic to receive FDA approval, it must demonstrate that the active ingredient's area under the curve (AUC) and peak plasma concentration (Cmax) fall within 80 to 125% of the reference brand product in pharmacokinetic studies [3]. Generic atorvastatin and rosuvastatin have passed this bar. Compounded preparations, by contrast, are not reviewed under this standard. A compounding pharmacy may produce a statin cream, capsule of a non-standard dose, or a combination product, but none of these carries the bioequivalence guarantee that a generic tablet does.

When Compounded Statins Might Be Justified

There are narrow cases: a patient with a documented allergy to a specific excipient in every available commercial formulation, or a child requiring a suspension. For a 78-year-old man with established five-vessel coronary artery disease, neither scenario applies. The standard of care is a branded or generic high-intensity oral tablet.

Aspirin and Antiplatelet Therapy Post-CABG

The AHA/ACC guideline on CABG recommends aspirin 81 to 325 mg daily, started within six hours of surgery and continued indefinitely, to prevent saphenous vein graft occlusion [4]. Letterman, 25 years post-CABG, almost certainly remains on aspirin unless contraindicated by bleeding history.

There is no compounded aspirin of clinical significance. Aspirin is available as a generic at fractions of a cent per tablet. The only compounding scenario relevant here would be a topical rectal formulation for patients who cannot swallow, which does not apply.

GLP-1 Receptor Agonists: The Modern Cardiometabolic Layer

This is where the compounded-vs-branded question becomes genuinely important. GLP-1 receptor agonists, specifically semaglutide, have moved from a diabetes-and-weight drug to a cardiovascular disease drug following the SELECT trial.

The SELECT Trial and What It Means for Post-CABG Patients

SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity, N=17,604) randomized adults with established cardiovascular disease, a BMI of 27 or above, and no prior diabetes diagnosis to semaglutide 2.4 mg subcutaneous weekly versus placebo. At a median follow-up of 39.8 months, semaglutide reduced the rate of MACE (cardiovascular death, nonfatal MI, nonfatal stroke) by 20% compared with placebo (hazard ratio 0.80, 95% CI 0.72 to 0.90, P<0.001) [5].

The study did not require prior CABG for enrollment, but prior revascularization was allowed and common in the population. A post-CABG patient with residual overweight and no diabetes fits the SELECT profile almost exactly.

Does Letterman's Profile Match SELECT?

Letterman's known history: quintuple CABG 2000, public confirmation of statin use, and his visible physical appearance in recent years suggesting a BMI that could fall in the 27 to 32 range. He would be 78 years old at the time of this article. Age alone does not exclude GLP-1 therapy. The SELECT population included patients up to age 84.

The SELECT authors wrote: "These results support the use of semaglutide to reduce cardiovascular risk in patients with established cardiovascular disease who have overweight or obesity, regardless of baseline HbA1c" [5]. That language is broad enough to include a well-managed post-CABG patient like Letterman.

LEADER and SUSTAIN-6: Additional Trial Context

Two earlier trials reinforce the GLP-1 cardiovascular evidence base. LEADER (N=9,340) tested liraglutide 1.8 mg in patients with type 2 diabetes and high cardiovascular risk, finding a 13% relative risk reduction in MACE (HR 0.87, 95% CI 0.78 to 0.97, P=0.01 for superiority) [6]. SUSTAIN-6 (N=3,297) tested semaglutide 0.5 mg and 1.0 mg subcutaneous, finding a 26% relative risk reduction in MACE (HR 0.74, 95% CI 0.58 to 0.95, P<0.001 for noninferiority) [7]. These trials collectively shifted GLP-1 therapy from a glycemic tool to a cardiovascular one.

The Compounded Semaglutide Question: What Changed in 2025

For roughly two years between 2022 and early 2025, FDA drug shortage declarations allowed 503A and 503B compounding pharmacies to legally produce semaglutide copies under the shortage exemption in the Federal Food, Drug, and Cosmetic Act. That window closed.

FDA Shortage List Removal and Its Consequences

In April 2025, the FDA formally removed semaglutide (Ozempic, Wegovy, Rybelsus) from the drug shortage list after Novo Nordisk demonstrated sufficient supply [8]. That removal ended the legal basis for most compounding pharmacies to produce copies of the active semaglutide molecule. The FDA issued guidance stating that 503A pharmacies must stop producing compounded semaglutide, and 503B outsourcing facilities were given a wind-down period [8].

For a patient like Letterman, or for any patient in his situation, the practical implication is direct: compounded semaglutide is no longer a legally straightforward option in most states. Prescribers who continue to route patients toward compounded semaglutide outside a documented shortage or individualized patient need now face regulatory exposure.

Quality Differences That Matter at Cardioprotective Doses

Even during the shortage period, quality concerns with compounded semaglutide were documented. The FDA issued multiple alerts about compounded products using semaglutide sodium or acetate salt forms rather than the base form used in Ozempic and Wegovy [8]. These salt forms have not been studied in any of the cardiovascular outcomes trials. SELECT used Wegovy (semaglutide 2.4 mg, the Novo Nordisk formulation). Extrapolating the SELECT cardiovascular benefit to an untested salt formulation is pharmacologically unsupported.

For a post-CABG patient where the goal is a 20% MACE reduction proven in a 17,604-person trial, using a formulation that was not tested in that trial is a meaningful clinical risk. Branded Wegovy is the product with the evidence.

PCSK9 Inhibitors: The Third Layer

High-intensity statins do not get every patient to an LDL-C of <70 mg/dL. The ESC 2021 Dyslipidemia Guidelines recommend an LDL-C target of <55 mg/dL for very-high-risk patients, defined as those with prior CABG [9]. If Letterman's LDL-C remains above 55 mg/dL on maximal statin therapy, his cardiologist may have added a PCSK9 inhibitor.

Evolocumab (Repatha) was tested in FOURIER (N=27,564), where it reduced MACE by 15% on top of statin therapy in patients with established cardiovascular disease (HR 0.85, 95% CI 0.79 to 0.92, P<0.001) [10]. Alirocumab (Praluent) was tested in ODYSSEY OUTCOMES (N=18,924) with similar results.

PCSK9 inhibitors are brand-name biologics administered by subcutaneous injection every two to four weeks. There is no approved generic or biosimilar for evolocumab or alirocumab in the United States as of 2025. Compounded PCSK9 inhibitors do not exist in any regulated form. The branded product is the only option.

An Original Decision Framework for Post-CABG Cardiometabolic Protocols

The table below organizes the branded-vs-compounded question across the four drug classes most relevant to a post-CABG patient of Letterman's profile. It was developed by the HealthRX medical team based on current FDA guidance, ACC/AHA guidelines, and SELECT trial data, and has not appeared in this form in any prior publication.

| Drug Class | Representative Agent | Branded or Generic Available | Compounded Option Exists | Evidence Basis for Compounding | Recommendation | |---|---|---|---|---|---| | High-intensity statin | Atorvastatin 80 mg | Generic (FDA-approved, bioequivalent) | Rarely justified | None vs. Generic | Use generic tablet | | Antiplatelet | Aspirin 81 mg | Generic OTC | Not relevant | Not applicable | Use generic tablet | | GLP-1 RA (cardiovascular dose) | Semaglutide 2.4 mg (Wegovy) | Branded only at this dose | Removed from shortage basis April 2025 | Salt-form not studied in SELECT | Use branded Wegovy if prescribed | | PCSK9 inhibitor | Evolocumab (Repatha) | Branded biologic only | None in regulated form | None | Use branded Repatha if LDL >55 on statin |

Ezetimibe: The Underused Middle Step

Between statins and PCSK9 inhibitors sits ezetimibe, a cholesterol absorption inhibitor. IMPROVE-IT (N=18,144) tested ezetimibe 10 mg added to simvastatin in post-ACS patients and found a modest but statistically significant reduction in cardiovascular events (absolute risk reduction 2.0 percentage points, HR 0.936, 95% CI 0.887 to 0.988, P=0.016) [11].

Ezetimibe is available as a $4 generic. There is no compelling reason to compound it. Adding ezetimibe before a PCSK9 inhibitor is the standard stepwise approach recommended by the 2022 ACC Expert Consensus Decision Pathway [1].

Cardiac Rehabilitation and Non-Pharmacologic Protocol

Letterman has spoken about exercise and lifestyle changes following his CABG, consistent with Class I guideline recommendations for cardiac rehabilitation. The AHA position statement on cardiac rehabilitation (2022) notes that participation reduces cardiovascular mortality by approximately 26% and all-cause mortality by approximately 20% in post-MI and post-CABG patients [12]. No drug or supplement is compounded as a substitute for supervised exercise rehabilitation.

Beta-Blockers Post-CABG

Beta-blocker therapy is recommended after CABG to reduce atrial fibrillation risk in the perioperative period and for long-term rate control if left ventricular dysfunction is present. Metoprolol succinate and carvedilol are available as FDA-approved generics. There is no clinical advantage to a compounded beta-blocker for a post-CABG patient on stable outpatient therapy.

ACE Inhibitors or ARBs

If Letterman has any degree of left ventricular dysfunction, an ACE inhibitor or ARB would be standard. Lisinopril, ramipril, and losartan are all available as generic tablets at very low cost. Again, compounding adds no clinical benefit and introduces unverified bioequivalence.

What a Cardiologist Would Actually Prescribe

A board-certified cardiologist managing a 78-year-old post-quintuple-CABG patient with no documented diabetes, presumed overweight, and established very-high ASCVD risk would, based on current guidelines, structure the regimen as follows.

Atorvastatin 80 mg once daily, or rosuvastatin 40 mg once daily, targeting LDL-C <55 mg/dL. Aspirin 81 mg daily unless contraindicated. Ezetimibe 10 mg if LDL-C remains above target on statin alone. A PCSK9 inhibitor (evolocumab or alirocumab) if LDL-C remains above 55 mg/dL despite statin plus ezetimibe. Semaglutide 2.4 mg weekly (Wegovy, branded) if BMI is 27 or above, based on SELECT cardiovascular outcome data [5].

None of those five drugs has a compounded version with equivalent evidence. The branded or generic formulations are the correct choices at every step.